CSChristina Spry

Christina Spry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christina Spry has a total of 158 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Plasmodium falciparum PPCS is a unique heteromeric complex with prokaryote-like activity and is a target of pantothenate analogs

    by Xiangning Liu, Ruitao Jin, Riyad Domingo, Timothy J. Kotzé, Jinming Guan, Anton R. Hamann, Annica Chu, Gene Hart-Smith, Christina Spry, Anna E. Sexton, et al.

    Coenzyme A (CoA) is essential for the intraerythrocytic stage of Plasmodium falciparum . Phosphopantothenoylcysteine synthetase (PPCS) catalyzes the second of five steps of the CoA biosynthesis pathway. Most apicomplexan parasites express one PPCS, whereas two PPCSs are expressed in P. falciparum . Here, we demonstrate that the two P. falciparum PPCSs ( Pf PPCSs) associate into a single, functional PPCS heteromeric complex that, unlike any other eukaryotic PPCS reported to date, is unable to use adenosine 5′-triphosphate. We identify a prokaryote-like helical component of Pf PPCS as important for the nucleotide specificity and potentially holding the key for its stringency for cytidine 5′-triphosphate. Moreover, we show that the complex is the target of multiple antiplasmodial pantothenate analogs and interacts with other analogs that target different steps in CoA biosynthesis/utilization. Our study provides opportunities for designing inhibitors that exploit the unique features of the Pf PPCS complex while, at the same time, avoiding the human counterpart, paving the way for additional therapies to combat malaria.

  • Open Access

    The heteromeric Plasmodium falciparum pantothenate kinase has only one active site and does not require Pf 14-3-3I for activity

    by Xiangning Liu, Christina Spry, Kevin J Saliba

    Coenzyme A (CoA) is an essential molecule for the intraerythrocytic stage of Plasmodium falciparum . Pantothenate kinase (PanK) catalyses the first step of the CoA biosynthesis pathway and functions as a homodimer in most organisms investigated thus far. P. falciparum possesses a novel heteromeric PanK complex composed of Pf PanK1, Pf PanK2 and Pf 14-3-3I. Using a mutagenesis approach, we generated 10 Pf PanK mutants and demonstrate that the Pf PanK complex has only one functional active site, with both Pf PanK1 and Pf PanK2 required for activity by the complex. We also show that Pf PanK2 is essential for normal intraerythrocytic parasite proliferation using a conditional knockdown system. 14-3-3 binding motifs generally contain a phosphoserine/threonine residue. Mass spectrometry analyses of phospho-peptide enriched, immunoprecipitated Pf PanK samples revealed phosphorylation sites in both Pf PanK1 and Pf PanK2 that were additional to the previously reported sites. To investigate the role of specific sites in Pf PanK1 and Pf PanK2 that may be involved in Pf 14-3-3I binding, five additional mutants were generated. Mutagenesis of four predicted Pf 14-3-3I binding sites in Pf PanK1 resulted in a significant reduction in the amount of Pf 14-3-3I bound to the Pf PanK complex, with S334 being the most likely binding site. Heterologous expression of the Pf PanK complex in an insect cell system yielded a small amount of soluble protein that assembled in situ into a functional complex. Combined results from heterologous expression and P. falciparum mutagenesis suggest that Pf 14-3-3I may not be essential for Pf PanK activity but may be important for stabilising the Pf PanK complex.

  • Open Access

    Flavin-deficient erythrocytes offer protection against malaria parasites

    by Ayman Hemasa, Welmoed van Loon, Jonathan Fu, Christina Spry, Julia Jäger, Donelly A. van Schalkwyk, Roberto Reverberi, Jules Ndoli, Frank P. Mockenhaupt, Carlo Contini, et al.

    Studies from the 1980s and 1990s conducted in Italy, where malaria was once endemic, hypothesized that individuals with erythrocytes deficient in flavin mononucleotide and flavin adenine dinucleotide (FAD)—collectively known as flavins—are partially protected against malaria. The condition was reported to be familial, consistent with a genetic element. This hypothesis, however, has never been tested. Using an erythrocyte FAD-dependent glutathione reductase activity assay, we identified individuals with flavin-deficient erythrocytes (FDE) in Ferrara, Italy (23% of 150 individuals screened), and in Huye, Rwanda (13% of 169 individuals). None of the individuals with FDE had a dietary riboflavin deficiency. Importantly, FDE from individuals in Ferrara, as well as erythrocytes depleted of flavins in vitro by riboflavin starvation, inhibited the intraerythrocytic proliferation of Plasmodium falciparum . We provide evidence that these erythrocytes are susceptible to oxidative stress, potentially explaining their inhibitory effect on parasite proliferation. Genetic analysis identified mutations in the FAD synthase gene of three individuals with FDE from Huye, consistent with a potential genetic basis.


  • Coenzyme A Biosynthesis

    by Kevin J. Saliba, Christina Spry

  • Mutation of the Plasmodium falciparum Flavokinase Confers Resistance to Roseoflavin and 8-Aminoriboflavin

    by Ayman Hemasa, Christina Spry, Matthias Mack, Kevin J. Saliba

    The riboflavin analogues, roseoflavin and 8-aminoriboflavin, inhibit malaria parasite proliferation by targeting riboflavin utilization. To determine their mechanism of action, we generated roseoflavin-resistant parasites by in vitro evolution. Relative to wild-type, these parasites were 4-fold resistant to roseoflavin and cross-resistant to 8-aminoriboflavin. Whole genome sequencing of the resistant parasites revealed a missense mutation leading to an amino acid change (L672H) in the gene coding for a putative flavokinase (PfFK), the enzyme responsible for converting riboflavin into the cofactor flavin mononucleotide (FMN). To confirm that the L672H mutation is responsible for the phenotype, we generated parasites with the missense mutation incorporated into the PfFK gene. The IC50 values for roseoflavin and 8-aminoriboflavin against the roseoflavin-resistant parasites created through in vitro evolution were indistinguishable from those against parasites in which the missense mutation was introduced into the native PfFK. We also generated two parasite lines episomally expressing GFP-tagged versions of either the wild-type or mutant forms of PfFK. We found that PfFK-GFP localizes to the parasite cytosol and that immunopurified PfFK-GFP phosphorylated riboflavin, roseoflavin, and 8-aminoriboflavin. The L672H mutation increased the KM for roseoflavin, explaining the resistance phenotype. Mutant PfFK is no longer capable of phosphorylating 8-aminoriboflavin, but its antiplasmodial activity against resistant parasites can still be antagonized by increasing the extracellular concentration of riboflavin, consistent with it also inhibiting parasite growth through competitive inhibition of PfFK. Our findings, therefore, are consistent with roseoflavin and 8-aminoriboflavin inhibiting parasite proliferation by inhibiting riboflavin phosphorylation and via the generation of toxic flavin cofactor analogues.


  • Open Access

    Mutation of the P. falciparum flavokinase confers resistance to roseoflavin and 8-aminoriboflavin

    by Ayman Hemasa, Christina Spry, Matthias Mack, Kevin J. Saliba

    We previously found that two riboflavin analogues, roseoflavin and 8-aminoriboflavin, inhibit malaria parasite proliferation by targeting riboflavin utilisation. To determine the mechanism of action of roseoflavin in P. falciparum , we generated roseoflavin-resistant parasites by in vitro evolution over 27 weeks. The roseoflavin-resistant parasites were found to be four times more resistant to roseoflavin and cross-resistant to 8-aminoriboflavin. Resistant parasites were subjected to whole genome sequencing and a missense mutation (T2015A), leading to an amino acid exchange (L672H), was detected in the gene coding for a putative flavokinase ( Pf FK), the enzyme responsible for converting riboflavin (vitamin B 2 ) into the cofactor flavin mononucleotide (FMN). To confirm that the L672H mutation is responsible for the observed phenotype, we generated parasites with the missense mutation incorporated into the Pf FK gene via a single-crossover recombination. The IC 50 values for roseoflavin (RoF) and 8-aminoriboflavin against the RoF-resistant parasites created through in vitro evolution were indistinguishable from the IC 50 values for parasites in which the missense mutation was specifically introduced into the native Pf FK. To investigate this mutation, we generated two parasite lines episomally-expressing GFP-tagged versions of either the wild type or mutant forms of flavokinase. We found that Pf FK-GFP localises to the parasite cytosol and that immunopurified Pf FK-GFP was active and phosphorylated riboflavin into flavin mononucleotide. The L672H mutation caused a reduction of the binding affinity, especially for the substrate RoF, which explains the resistance phenotype. The mutant Pf FK is no longer capable of phosphorylating 8-aminoriboflavin, but its antiplasmodial activity against resistant parasites can still be antagonised by increasing the extracellular concentration of riboflavin, consistent with the compound also inhibiting parasite growth through competitive inhibition of Pf FK. Our findings, therefore are consistent with roseoflavin and 8-aminoriboflavin inhibiting parasite growth by inhibiting FMN production, in addition to the generation of toxic flavin cofactor analogues.

  • Open Access

    Discovery of antiplasmodial pyridine carboxamides and thiocarboxamides

    by Alexa Redway, Christina Spry, Ainka Brown, Ursula Wiedemann, Imam Fathoni, Larnelle F. Garnie, Deyun Qiu, Timothy J. Egan, Adele M. Lehane, Yvette Jackson, et al.


  • Open Access

    A screen of drug-like molecules identifies chemically diverse electron transport chain inhibitors in apicomplexan parasites

    by Jenni A. Hayward, F. Victor Makota, Daniela Cihalova, Rachel A. Leonard, Esther Rajendran, Soraya M. Zwahlen, Laura Shuttleworth, Ursula Wiedemann, Christina Spry, Kevin J. Saliba, et al.

    Apicomplexans are widespread parasites of humans and other animals, and include the causative agents of malaria (Plasmodium species) and toxoplasmosis (Toxoplasma gondii). Existing anti-apicomplexan therapies are beset with issues around drug resistance and toxicity, and new treatment options are needed. The mitochondrial electron transport chain (ETC) is one of the few processes that has been validated as a drug target in apicomplexans. To identify new inhibitors of the apicomplexan ETC, we developed a Seahorse XFe96 flux analyzer approach to screen the 400 compounds contained within the Medicines for Malaria Venture ‘Pathogen Box’ for ETC inhibition. We identified six chemically diverse, on-target inhibitors of the ETC in T. gondii, at least four of which also target the ETC of Plasmodium falciparum. Two of the identified compounds (MMV024937 and MMV688853) represent novel ETC inhibitor chemotypes. MMV688853 belongs to a compound class, the aminopyrazole carboxamides, that were shown previously to target a kinase with a key role in parasite invasion of host cells. Our data therefore reveal that MMV688853 has dual targets in apicomplexans. We further developed our approach to pinpoint the molecular targets of these inhibitors, demonstrating that all target Complex III of the ETC, with MMV688853 targeting the ubiquinone reduction (Qi) site of the complex. Most of the compounds we identified remain effective inhibitors of parasites that are resistant to Complex III inhibitors that are in clinical use or development, indicating that they could be used in treating drug resistant parasites. In sum, we have developed a versatile, scalable approach to screen for compounds that target the ETC in apicomplexan parasites, and used this to identify and characterize novel inhibitors.


  • Open Access

    Chemical Validation of Mycobacterium tuberculosis Phosphopantetheine Adenylyltransferase Using Fragment Linking and CRISPR Interference**

    by Jamal El Bakali, Michal Blaszczyk, Joanna C. Evans, Jennifer A. Boland, William J. McCarthy, Imam Fathoni, Marcio V. B. Dias, Eachan O. Johnson, Anthony G. Coyne, Valerie Mizrahi, et al.

    The coenzyme A (CoA) biosynthesis pathway has attracted attention as a potential target for much‐needed novel antimicrobial drugs, including for the treatment of tuberculosis (TB), the lethal disease caused by Mycobacterium tuberculosis (Mtb). Seeking to identify inhibitors of Mtb phosphopantetheine adenylyltransferase (MtbPPAT), the enzyme that catalyses the penultimate step in CoA biosynthesis, we performed a fragment screen. In doing so, we discovered three series of fragments that occupy distinct regions of the MtbPPAT active site, presenting a unique opportunity for fragment linking. Here we show how, guided by X‐ray crystal structures, we could link weakly‐binding fragments to produce an active site binder with a KD Mtb activity, as demonstrated using CRISPR interference. This study represents a big step toward validating MtbPPAT as a potential drug target and designing a MtbPPAT‐targeting anti‐TB drug.